{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:39:34Z","timestamp":1790285974002,"version":"4.1.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AN2 Therapeutics, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Mycobacterium abscessus is a highly drug-resistant non-tuberculous mycobacterium (NTM) for which treatment is limited by the lack of active oral antimycobacterials and frequent adverse reactions. Epetraborole is a novel oral, boron-containing antimicrobial that inhibits bacterial leucyl-tRNA synthetase, an essential enzyme in protein synthesis, and has been shown to have anti-M. abscessus activity in preclinical studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine epetraborole MIC distribution for 147 recent M. abscessus isolates via broth microdilution.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>M. abscessus isolates collected in 2021 from the USA (n\u200a=\u200a122) from pulmonary sources and during 2019\u201322 predominantly from Europe (n\u200a=\u200a25) from pulmonary and extrapulmonary sources had MICs determined by broth microdilution according to CLSI guidelines for epetraborole and a panel of 12 other antimycobacterials. Descriptive analyses were done on the MIC values.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 147 M. abscessus isolates, 101 were subspecies abscessus, 6 were bolletii and 40 were massiliense. Epetraborole MICs ranged from 0.03 to 0.25\u2005mg\/L and were consistent across subspecies. Epetraborole MIC50\/MIC90 for all isolates were 0.06\/0.12\u2005mg\/L. When stratified by subspecies, amikacin resistance, clarithromycin resistance and morphotype, the MIC50\/MIC90 values remained 0.06\/0.12\u2005mg\/L.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Epetraborole demonstrated potent in vitro activity against M. abscessus with MICs from 0.03 to 0.25\u2005mg\/L and consistent activity against all subspecies, resistance phenotypes and morphotypes. These data support clinical evaluation of epetraborole as a therapeutic option for M. abscessus disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae461","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T09:48:09Z","timestamp":1735638489000},"page":"713-716","source":"Crossref","is-referenced-by-count":3,"title":["<i>In vitro<\/i> susceptibility of 147 international clinical <i>Mycobacterium abscessus<\/i> isolates to epetraborole and comparators by broth microdilution"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7598-7362","authenticated-orcid":false,"given":"Minh-Vu H","family":"Nguyen","sequence":"first","affiliation":[{"name":"Division of Mycobacterial and Respiratory Infections, Department of Medicine, National Jewish Health , Denver, CO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius","family":"Calado Nogueira de Moura","sequence":"additional","affiliation":[{"name":"Division of Mycobacterial and Respiratory Infections, Department of Medicine, National Jewish Health , Denver, CO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany R","family":"Keepers","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, AN2 Therapeutics, Inc , Menlo Park, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-2003","authenticated-orcid":false,"given":"Jakko","family":"van Ingen","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Radboud University Medical Center , Nijmegen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L","family":"Daley","sequence":"additional","affiliation":[{"name":"Division of Mycobacterial and Respiratory Infections, Department of Medicine, National Jewish Health , Denver, CO ,","place":["USA"]},{"name":"Division of Infectious Diseases, Department of Medicine, University of Colorado , Aurora, CO ,","place":["USA"]},{"name":"Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado , Aurora, CO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"2025030423053545200_dkae461-B1","doi-asserted-by":"publisher","first-page":"115882","DOI":"10.1016\/j.diagmicrobio.2022.115882","article-title":"In vitro susceptibility patterns for rapidly growing nontuberculous mycobacteria in the United States","volume":"105","author":"Hunkins","year":"2023","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2025030423053545200_dkae461-B2","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025030423053545200_dkae461-B3","doi-asserted-by":"publisher","first-page":"909274","DOI":"10.3389\/fmicb.2022.909274","article-title":"The impact of nontuberculous mycobacteria species on mortality in patients with nontuberculous mycobacterial lung disease","volume":"13","author":"Wang","year":"2022","journal-title":"Front Microbiol"},{"key":"2025030423053545200_dkae461-B4","doi-asserted-by":"publisher","first-page":"e0115621","DOI":"10.1128\/AAC.01156-21","article-title":"Epetraborole is active against Mycobacterium abscessus","volume":"65","author":"Ganapathy","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2025030423053545200_dkae461-B5","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1128\/AAC.02058-12","article-title":"Discovery of a novel class of boron-based antibacterials with activity against Gram-negative bacteria","volume":"57","author":"Hernandez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2025030423053545200_dkae461-B6","doi-asserted-by":"publisher","first-page":"5936","DOI":"10.3390\/ijms22115936","article-title":"A screening of the MMV pandemic response box reveals epetraborole as a new potent inhibitor against Mycobacterium abscessus","volume":"22","author":"Kim","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025030423053545200_dkae461-B7","doi-asserted-by":"publisher","first-page":"e1009965","DOI":"10.1371\/journal.ppat.1009965","article-title":"Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline","volume":"17","author":"Sullivan","year":"2021","journal-title":"PLoS Pathog"},{"key":"2025030423053545200_dkae461-B8","volume-title":"Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes\u2014Second Edition: M24S","author":"CLSI","year":"2023"},{"key":"2025030423053545200_dkae461-B9","volume-title":"Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes\u2014Third Edition: M24","author":"CLSI","year":"2018"},{"key":"2025030423053545200_dkae461-B10","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1128\/JCM.00147-16","article-title":"GenoType NTM-DR for identifying Mycobacterium abscessus subspecies and determining molecular resistance","volume":"54","author":"Kehrmann","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2025030423053545200_dkae461-B11","doi-asserted-by":"publisher","first-page":"116526","DOI":"10.1016\/j.diagmicrobio.2024.116526","article-title":"Evaluation of the GenoType NTM-DR line probe assay for nontuberculous mycobacteria using whole genome sequences as reference standard","volume":"110","author":"Epperson","year":"2024","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2025030423053545200_dkae461-B12","doi-asserted-by":"publisher","first-page":"e0131822","DOI":"10.1128\/jcm.01318-22","article-title":"MGIT enriched shotgun metagenomics for routine identification of nontuberculous mycobacteria: a route to personalized health care","volume":"61","author":"Schildkraut","year":"2023","journal-title":"J Clin Microbiol"},{"key":"2025030423053545200_dkae461-B13","doi-asserted-by":"publisher","first-page":"e02420-20","DOI":"10.1128\/AAC.02420-20","article-title":"A leucyl-tRNA synthetase inhibitor with broad-spectrum anti-mycobacterial activity","volume":"95","author":"Ganapathy","year":"2023","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/3\/713\/61298203\/dkae461.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/3\/713\/61298203\/dkae461.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T23:05:50Z","timestamp":1741129550000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/3\/713\/7935058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":13,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,12,31]]},"published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae461","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,12,31]]}}}